In this study, we investigated the suppressive effect of a short hairpin RNA delivered by a lentiviral vector (LV-shRNA) against human papillomavirus (HPV) type 18 E6 on the expression of the oncogenes E6 and E7 in cervical cancer HeLa cells both in vitro and in vivo. The LV-shRNA effectively delivered the shRNA to HeLa cells and lead to a dose-dependent reduction of E7 protein and the stabilization of E6 target proteins, p53 and p21. Low-dose infection of HeLa cells with LV-shRNA caused reduced cell growth and the induction of senescence, whereas a high-dose infection resulted in specific cell death via apoptosis. Transplant of HeLa cells infected with a low dose of LV-shRNA into RagÀ/À mice significantly reduced the tumor weight, whereas transplant of cells infected with a high dose resulted in a complete loss of tumor growth. Systemic delivery of LV-shRNA into mice with established HeLa cell lung metastases led to a significant reduction in the number of tumor nodules. Our data collectively suggest that lentiviral delivery is an effective way to achieve stable suppression of E6/E7 oncogene expression and induce inhibition of tumor growth both in vitro and in vivo. These results encourage further investigation of this form of RNA interference as a promising treatment for cervical cancer.
Introduction
Human papillomavirus (HPV) are non-enveloped double stranded DNA viruses that cause a range of proliferative lesions upon infection of epithelial cells. High-risk HPV types (such as type 16, 18 and 45) are also associated with the development of a variety of tumor entities in humans, including cervical carcinoma that represents the second most common cancer in women worldwide. [1] [2] [3] Indeed, HPV-related cancers have been estimated to account for 5% of all human cancers. 4 It has been shown that expression of the E6/E7 oncogenes from high-risk HPV is the primary cause of cervical cancer and their continuous expression is necessary for keeping cancer cell alive. [5] [6] [7] This therefore provides a rational target for the application of therapeutic nucleic acids.
RNA interference (RNAi) has been proved to be a powerful tool to specifically silence gene expression and holds a great promise for the treatment of genetic disorders, viral diseases and cancer. [8] [9] [10] [11] [12] Previous studies have demonstrated that small interference RNA (siRNA) can suppress HPV E6 and/or E7 expression in various cancer cell lines. [13] [14] [15] [16] [17] [18] However, the suppression in these studies was either transient (owing to the short half-life of siRNA), against only one target, or not all cells were transfected leading to escape. We wished to improve these results by using shRNA delivered by a third-generation lentiviral vector for a more effective, stable and long-term RNAi. The advantage of using the lentiviral delivery system compared with synthetic and vector-borne siRNA is the ability to stably transduce dividing and nondividing cells with relatively high efficiency. [19] [20] [21] In addition, lentivirus is non-toxic and minimally immunogenic as no viral genes are encoded in the vector genome. As a result, it has been possible to obtain long-term gene expression in many different tissues and organs. As a gene delivery system, lentiviral vector has been explored for preclinical or clinical application and shown promising results. [22] [23] [24] HPV E6 and E7 transform the cervical epithelial cells through the interaction with, and elimination of, the tumor-suppressive proteins p53 and pRB. 25 Therefore, suppression of E6 and E7 expression by RNAi will lead to an accumulation of p53 and pRB and trigger cells to undergo apoptosis or senescence. 5, 26 Butz et al. 13 showed that vector-borne siRNA against HPV 18 E6-class I transcripts-induced apoptosis in transfected HeLa cells. However, another study using synthetic siRNA against HPV 18 E7 bases 142-160, a region that can target both E6 and E7, showed only senescence in HeLa cells.
14 Using a different approach, Horner et al. 26 overexpressed BPV E2 in order to suppress both HPV 18 E6 and E7 and found HeLa cells underwent senescence, but not apoptosis. Other methods that have inhibited only E6 have resulted in limited apoptosis of cervical cancer cells. 27, 28 Obviously, a conclusive picture has not emerged from these studies.
To investigate the above issue with a stable E6/E7 suppression system and viral vector and investigate the potential role for shRNA in the treatment of cervical cancer, we used lentiviral vector to deliver shRNA to HeLa cells that could permanently target both E6 and E7. We show both in vitro and in vivo that the shRNA delivered by a lentivirus can effectively, specifically and stably suppress HPV 18 E6 and E7 expression. We also demonstrated that tumor growth can be completely inhibited from mice by RNAi treatment. Using this system, we are able to show that the cancer cells infected with low doses of this short hairpin RNA delivered by a lentiviral vector (LV-shRNA) generally undergo senescence, but with higher doses die through apoptosis.
Materials and methods
shRNA design and lentiviral packing plasmids We followed the criteria described by Tom Tuschl and used the computer program (web site http:// www.mpibpc.gwdg.de/abteilungen/100/105/sirna.html) to design shRNAs based on HPV 18E6 mRNA sequence. Two of them were specially chosen for this study, 18E6-1 targets at the common sites of all mRNA classes, whereas 18E6-2 targets only class I mRNA. 29 The advantage of selecting E6 regions was the ability to simultaneously knockdown both E6 and E7 expression as they are bicistronically transcribed (Figure 1 ). The shRNA expression cassette contained 19 nucleotide (nt) of the target sequence followed by the loop sequence (TTCAAGA GA), reverse complement to the 19 nt, stop codon for U6 promoter and Xho1 site (18E6-1: 5 0 -TAGGTATTT GAATTTGCATTTCAAGAGAATGCAAATTCAAAT ACCTTTTTTTC; 18E6-2: 5 0 -TCAGAAAAACTTAGA CACCTTCAAGAGAGGTGTCTAAGTTTTTCTGTT TTTTC). The shRNA cassettes and their complementary strands were synthesized (PROLIGO, Lismore, Australia) and annealed in the annealing buffer (100 mM K-acetate, 30 mM HEPES-KOH (pH 7.4), 2 mM Mg-acetate) by heating to 951C for 5 min followed by cooling to room temperature. The resulting double-strand oligo-DNA was cloned into plasmid pLentiLox3.7 (pLL3.7, a gift from Dr Luk van Parijs, MIT, Cambridge) at the HapI and XhoI sites (Figure 1 ). The insert was confirmed by both restriction enzyme digestion and DNA sequencing. As Figure 1 indicates, Plasmid pLLl3.7 (transfer vector) has a self-inactivating LRT 20 for the biosafety consideration. Plasmid pLL3.7 also contains an eGFP gene under cytomegalovirus (CMV) promoter, this enables monitoring the infection of lentiviruses by eGFP expression. The lentiviral packaging plasmids pRSVRev, pMDLgpRRE and pMD.G (contains VSV.G gene) are gift from Dr Inda Vermer (Salk Institute, San Diego, CA). These packaging plasmids were described in detail by Dull et al. 30 and were used for third-generation lentiviral vector production.
Production of lentiviruses and titration Lentiviral production and titration were as described previously. 29 Briefly, the packing plasmids and pLL3.7 were amplified in Escherichia coli and purified using W/Endo-free Qiagen Maxi-Prep Kits (Promega, Sydney Australia) according to the manufacturer's instructions. Packing cell line 293T cells were transfected with 6.6 mg pLL3.7 (7insert) and 3.3 mg of each packaging plasmid in 133 ml 1.25 M CaCl 2 , 0.5 ml H 2 O and 0.66 ml 2 Â HEPESbuffered saline (140 mM NaCl, 1.5 mM Na 2 HPO 4 , 50 mM HEPES, pH 7.05) in a T 75 flask. The viral supernatant was harvested and concentrated 40-50 times using Vivaspin 20 ml Concentrators (100 MW, VivaScience Sartorius Group, Sydney, Australia). The lentiviral stocks were stored in small aliquot at À801C for titration and cell infection.
Cell infection, crystal violet staining and flow cytometry analysis HeLa cells were plated in 24-well plates (2.5 Â 10 4 cells/ well) or six-well plates (1 Â 10 5 cells/well) or T 75 flasks (2 Â 10 6 cells) and were cultured overnight. Lentiviruses were diluted in 0.2 ml (24-well plate) or 0.5 ml (six-well plate) or 2 ml (flask) Dulbecco's modified Eagle's medium Northern blot analysis Total RNA was extracted from trypsinized HeLa cells infected or uninfected with lentiviruses using the method described previously. 31 Fifteen micrograms total RNA was digested with DNase I before being separated in a 12% polyacrylamide/urea gel and blotted onto a Nylon N þ membrane (Amersham). The RNA was bound to the membrane by ultraviolet (UV) crosslinking before being pre-hybridiszed with hybridization buffer (0.5 M sodium phosphate (pH ¼ 7.5), 7% sodium dodecyl sulfate (SDS), and 1 mM ethylenediaminetetraacetic acid) for 2 h at 681C. The blot was hybridized with a 32 P end-labelled oligo-DNA probe at 421C overnight before being washed once with 1 Â standard sodium citrate (SSC)/1%SDS and three times with 0.5 Â SSC/0.1%SDS at 421C and exposed to X-ray film.
Western blotting
The Western blotting protocol was as described previously. 29 Briefly, HeLa cell lysates were prepared in radioimmunoprecipitation assay buffer and their protein concentrations were determined using the BCA Protein Assay Kit (Progen, Darra, Australia). For electrophoresis, 30-40 mg of total protein in 2 Â loading buffer was loaded to each well of a 10% (w/v) SDS-PAGE gel. After electrotransferring, the blot was blocked and probed with primary antibody at 41C followed by incubation with horseradish peroxidase-conjugated secondary antibody before detection by ECL. All primary antibodies were used at 1/1000 dilution. Anti-p53 and anti-tubulin monoclonal antibodies were purchased from Sigma (Sydney, Australia). Anti-p21 antibody, anti-HPV 18E7 and anti-MAP LC3 antibody were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-poly-ADP-ribose polymerase (PARP) antibody was from Cell Signalling Technology (Danvers, MA).
Real-time polymerase chain reaction (PCR) to determine gene copy number
The primers for eGFP (forward, 5 0 -GCA GTG CTT CAG CCG CTA C-3 0 ; reverse, 5 0 -AAG AAG ATG GTG CGC TCC TG-3 0 ) and human 18S rDNA (forward, 5 0 -CCA TCG AAC GTC TGC CCT A-3 0 ; reverse, 5 0 -TCA CCC GTG GTC ACC ATG-3 0 ) were as described previously.
32 18S rDNA was a single copy gene and was used as a control to normalize eGFP gene copy number. Genomic DNA was isolated from infected or control HeLa cells using DNA-easy Kit (QIAGene, Doncaster, Australia). Real-time PCR was carried out using a RotorGene RG-3000 (Corbett Research, Australia) with the following program: pre-heating 951C 10 min; then 40 cycles of 941C 15 s; 581C 30 s; and 721C 30 s. EGFP standards were series 10-fold dilutions of pLL3.7 plasmid DNA and rDNA standards were similarly diluted HeLa genomic DNA. The results were analyzed using RotorGene6 software and presented as copies/genome7s.e.m.
Cell viability assay
HaLa cells infected or uninfected with LVs were grown for 4 days and were trypsinized, counted and seeded in six-well plates (5 Â 10 5 /well) for overnight incubation. The cells were washed twice with PBS and were covered with 250 ml of 2mg/ml MTT (3-[4,5-dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) and 750 ml PBS for incubation at 371C for 3 h. Dimethyl sulfoxide, 750 ml, was added to each well for incubation at room temperature for 10 min before the supernatant was transferred to a 96-well plate for absorbance measurement at 595 nm.
Animal experiments
HeLa cells were infected with LVs in T 75 flasks as described above and harvested 2 days post-infection. The cells were washed with PBS, counted and resuspended in PBS at 1 Â 10 7 /ml. Female Rag À/À mice (5-6 weeks old, 5-10 mice/group) were injected with 0.1 ml cell suspension subcutaneously to the neck scruff and tumor growth was monitored. At day 17 or 21, the tumor was collected, pictured and weighted. For lung metastases experiments, Rag À/À mice were injected with 1 Â 10 6 HeLa cells via the tail-vein. Lungs were examined histologically for metastases every week until 7 weeks when the tumor nodules were established. The mice were then randomly grouped (4 mice/group) and injected with 2 Â 10 7 infectious units of either LV-18E6-1 or LV-PLL at weeks 8 and 9. At week 10, lungs were colleted for frozen sections, which were immunoflourescently stained with monoclonal antihuman major histocompatability complex (MHC) class I antibody conjugated with fluorescein isothiocyanate (Sigma) as described previously 33 or lungs were fixed for histological examination. All experiments were approved by the University of Queensland Animal Ethics Committee.
Caspase-3 and -7 activity assay Caspase-Glo TM 3/7 assay kit (Promega, Australia) was used to analyze caspase-3/7 activity of the infected or uninfected HeLa cells according the manufacturer's instructions. Briefly, 2 days after infection with LV, HeLa cells were harvested and counted. Twenty thousands cells in 50 ml DMEM were transferred to each well of a whitewalled 96-well plate (Perkin-Elmer, Australia) and 50 ml caspase buffer was added. After 30 min incubation at room temperature, the plates were read on a TopCount-NXT (PACKARD, Australia) for luminescence.
Senescence-associated b-galactosidase assay HeLa cells infected with low-dose lentiviruses were cultured for 1 week and harvested for counting. The cells were seeded (5 Â 10 5 /well) in six-well plates and incubated overnight before being fixed with 3% paraformaldehyde/ PBS for 5 min at 41C. The cells were then washed 3 Â with PBS and covered with 0.7 ml X-gal staining solution 34 and incubated at 371C overnight (or until blue precipitate was visible inside cells). The plates were viewed under light microscopy and positive cells were counted per view using double-blind methods.
Data analysis
Data were collected and expressed as mean7s.d. for each group and unpaired t-test was used to discriminate the significant differences (two-tailed, Po0.05) between two groups.
Results
Lentiviruses effectively transduce HeLa cells and deliver shRNA Three LVs were produced: LV-18E6-1 carries shRNA 18E6-1, LV-18E6-2 carries shRNA 18E6-2 and LV-PLL carries only pLL3.7 ( Figure 1 ). All LVs expressed eGFP, which allowed for tittering in 293T cells as well as measuring their infection efficiency in HeLa cells. When 10 infectious unit/cell of each lentivirus was applied to HeLa cells, almost 100% cells were eGFP positive (Figure 2a and b) . For convenience, we designated this dose as 1 Â . Increasing the LV dose led to stronger eGFP expression (Figure 2a (Figure 2c ). These data confirm that LV can effectively transduce and deliver shRNA to HeLa cells.
Stable suppression of E7 and E6 expression in HeLa cells
Two days after infection, HeLa cells infected with LV-18E6-1 became more granular, compared to cells infected with LV-18E6-2, LV-PLL or uninfected controls (data not shown). As HPV E6 and E7 are transcribed bi-cistronically, the degradation of 18E6 mRNA by (Figure 3a) . However, no reduction of E7 protein level was observed in LV-18E6-2-infected HeLa cells (Figure 3a ). This could be owing to the nature of 18E6-2 targeting only class I mRNA and at the spliced region of other mRNA classes or simply because of the ineffective sequence. To determine if longer suppression of E7 than synthetic siRNA could achieve HeLa cells were infected with a 1 Â dose lentivirus and E7 levels were determined at 1 and 2 weeks post-infection. Constant suppression was observed at both time points, although the level was slightly higher at week 2 than week 1 (Figure 3b ). To observe E7 protein reduction in a dosedependent way, we infected HeLa cells with increasing doses of LV-18E6-1 and detected the E7 protein level at day 2 post-infection. We did observed a dose-dependent reduction of E7 protein in infected HeLa cells (Figure 3c ). E6 expression was limited to surrogate markers as Western blotting proved unsuccessful with several commercial anti-E6 antibodies. However, E6, via E6-associated proteins; causes p53 protein degradation, therefore, any increase in p53 levels would indicate the loss of E6 protein. We indeed observed increased levels of p53 in cells infected with LV-18E6-1 but not LV-PLL (Figure 3d ). To further confirm this, we detected the protein levels of p21, a p53-responsive gene, and observed a modest increase in LV-18E6-1-infected cells but not the PLL-or 18E6-2-infected cells (Figure 3d ). Taken together, these results suggest that the infection of LV-18E6-1 can induce a stable suppression of E6 and E7 expression in HeLa cells.
LV-18E6-1 infection causes low cell viability and specific cell death
To examine if the suppression of E6 and E7 by LV-18E6-1 would affect cell growth or metabolism, we carried out MTT assay using equal number of cells infected with 1 Â dose LVs. There was a significant reduction in the ability to transform MTT of 18E6-1-infected cells compared with other infected or uninfected HeLa cells (Figure 4a ), suggesting that LV-18E6-1 infection caused lower cell viability. When we infected HeLa cells with high doses (4 Â and 5 Â ) of LVs, we noticed cell death at day 5 post-infection with LV-18E6-1, whereas cells infected with LV-PLL or LV-18E6-2 were unaffected (Figure 4b ). This indicates that high-dose infection of LV-18E6-1 could cause specific cell death to HeLa cells. To further confirm the specificity, we infected two other cervical cancer cell lines, C33A (HPV negative with mutant p53 and pRB proteins 35 ) and SiHa (HPV type 16 positive) with the same LVs. Unlike HeLa cells, C33A and SiHa cells were not killed by the infection with LV-18E6-1 even at high doses.
Inhibiting tumor growth in vivo
To test the effectiveness of LV-shRNA in vivo, we conducted animal experiments using Rag -/-mice xenograft Lentivirus-shRNA suppresses E6/E7 in vitro and in vivo W Gu et al models. We firstly tested 1 Â dose infection with LV-18E6-1 and -2 and observed a significant tumor weight reduction in the LV-18E6-1 but not -2 group, compared to HeLa alone or LV-PLL (Figure 5a ). Visual inspection of these tumors indicated that all tumors received LVs were green (eGFP positive), whereas tumors from HeLa alone were white. This result was consistent with our in vitro data. We then tested a high-dose infection (4 Â ) of LV-18E6-1 and observed that all mice were tumor free ( Figure 5b ). This is a good demonstration of complete ablation of HPV-mediated tumors in vivo using RNA interference. To test LV-shRNA in established tumors we used a lung metastases model in which the lung tumors were firstly established over several week period and LV-shRNAs were then systemically applied. Histological examination indicated that there were significantly fewer tumor nodules present in lungs from 18E6-1 group compared to the PLL group (Figure 5c ). We confirmed this by using immunofluorescent labelling of HeLa cells on frozen lung sections with anti-human MHC class I antibody, which also indicated a reduction in lung tumors in 18E6-1-injected mice (Figure 5d ). These data suggest that the knockdown of E6 and E7 using LV-shRNA can significantly reduce tumor growth at low doses and completely stop tumor growth at high doses in vivo. Systemic injection of LV-shRNA can be effective at targeting and reducing tumor growth.
Cell death through apoptosis after high-dose infection
Data from previous studies showed that apoptosis, 13 senescence 14 or both 26 can occur in cervical cancer cells when HPV type 16 or 18 E6 and E7 have been suppressed. To investigate if the cell death after high-dose infection of LV-18E6-1 was via apoptosis, we analyzed caspase-3/7 activity in infected HeLa cells. We observed a dosedependent increase of caspase-3/7 activity in LV-18E6-1-infected HeLa cells compared with those infected with LV-PLL (Figure 6a) . To confirm this, we detected the cleavage of PARP, a cleavage target of caspase-3. The increased levels of degraded PARP in LV-18E6-1-infected HeLa cells were observed as infection doses increased, but not in cells infected with LV-PLL (Figure 6b ). To further investigate the apoptotic pathway, we infected HeLa cells overexpressing Bcl-2 (Bcl-2-HeLa) with LV-18E6-1. We observed that even at a high dose of LV infection, there were no obvious apoptotic cells in Bcl-2-HeLa cells, whereas apoptotic cells were easily found in the parent HeLa cells (Figure 6c) . The above data collectively confirm that high-dose LV infection can lead to apoptosis.
Senescence after low-dose infection
To examine if HeLa cells infected with low-dose LV were undergoing senescence, we assayed for the presence of senescence-associated b-galactosidase (SAb-gal) activity, a known marker for cellular senescence. 34 We observed large numbers of SAb-gal-positive HeLa cells on day 7 following infection with 1 Â and 3 Â doses of LV-18E6-1 (Figure 7a and b) . This result suggests that HeLa cells infected with low doses of LV-18E6-1 mainly undergo senescence at a later stage.
Discussion
We have demonstrated in this study that shRNA delivered by a lentivirus could effectively, specifically and stably suppress targeted oncogene E6 and E7 expression in cervical cancer HeLa cells and led to apoptosis and senescence of these cells. Using a tumor 
transplant model, we further demonstrated that LV-shRNA could partially or completely inhibit tumor growth depending on the infection doses. More importantly, in an established lung metastases model, we showed that systemic delivery of LV-shRNA could inhibit or kill these cells and led to the significant reduction of tumor nodules in the lung. These results encourage further investigation of RNAi as a potential treatment for cervical cancer. Although the knockdown of HPV E6 and E7 expression in HeLa cells has been reported by a few groups using siRNA, 14, 13, 18 we showed here a stable knockdown of E6 or E7 in HeLa cells (at least 2 weeks) with LV-shRNA. In previous reports, Yoshinouchi et al. 17 showed that synthetic HPV 16 siRNA induced a modest reduction in tumor growth of SiHa cells in NOD/ SCID mice. Given this was an siRNA with a limited halflife, it was a remarkable result. However, the advantage of using 9 lentiviral delivery system is that essentially 100% HeLa cells can be infected and multiple copies of shRNA expression construct can be delivered and integrated into the genome of infected cells, which would ensure a maximal and long-lasting knockdown of the target gene.
It was reported that suppression of E6 and E7 expression in cervical cancer cells with synthetic or DNA vector-borne siRNA can lead to slowed growth, 17 apoptosis 13, 15 or senescence. 14 With the LV-shRNA, we showed that simultaneously targeting both E6 and E7 resulted in senescence at low-dose infection. This result is consistent 14 with previous reports in HeLa cells. For example, Hall and Alexander targeted just the HPV18 E7 gene, but showed both E6 and E7 mRNA were downregulated in HeLa cells and the cells underwent senescence. Previous studies using BPV E2 protein to suppress both HPV18 E6 and E7 in HeLa cells also showed the loss of cell growth and senescence. 26 Therefore, the low-dose LV infection seems to mimic the use of synthetic siRNA or BPV E2 in above studies where both E6 and E7 were suppressed and the senescence and slowed cell growth were the major outcome. We further confirmed these outcomes by MTT assay and in vivo tumor test after low-dose infection in the current study.
Butz et al. 13 targeted HPV18E6 in HeLa cells, but in a region of the E6 intron (bp385-403) and showed that while E6 mRNA was reduced, E7 protein levels remained unaffected and cells underwent apoptosis. In HeLa cells, the loss of E6 in the presence of E7 has previously been shown to result in apoptosis but only after several days. 35 However, our data indicated that LV-18E6-1 clearly reduced E7 protein levels and led to an earlier apoptosis. A possible explanation for the difference is that apart from the longer lasting suppression of E6 and E7, the high-dose infection of LV-18E6-1 itself may provide additional stress to the cells. For instance, the multi-copy gene integration into the genomic DNA and the high-level eGFP expression could lead to increased susceptibility to cell death or apoptosis. This explanation is supported by our previous data showing that HeLa cells infected with low-dose LV-18E6-1 were more sensitive to the anticancer drug cisplatin. 29 Therefore, using the LV-shRNA system, with longer lasting suppression of E6 and E7, HeLa cells become very sensitive to cellular stress and the viral infection (especially at high doses) may act as a factor triggering the apoptosis pathway. However, without E6 and E7 suppression, infection with even high-dose lentivirus carrying either transfer vector only (LV-PLL) or an ineffective shRNA (LV-18E6-2) had only limited impact on cell survive, cell growth and tumor growth.
The apoptosis induced by LV-18E6-1 is clearly activated via the intrinsic apoptotic pathway as Bcl-2-HeLa cells were insensitive to the loss of E6 and E7 because Bcl-2 is an antiapoptotic protein that balances the release of cytochrome c from the mitochondria. 36 It is known that DNA damage or ongoing accumulation of cellular damage could lead to the activation of the intrinsic pathway. We speculate that the multi-copy gene integration and the high levels of eGFP expression may act as DNA or cellular damage factors and activate intrinsic apoptotic pathway. In addition, the DNA damage could also activate p53, which together with the stabilization of p53 after LV-18E6-1 infection could also induce the generation of reactive oxygen species, and the resulting oxidative damage may trigger apoptosis. [37] [38] [39] Some studies have suggested that autophagy could be another means by which cells can die, especially following viral infection. 40 , 41 However, we tested this possibility and found no evidence of autophagy in these cells (data not shown).
A major concern with lentiviral delivery is the biosafety issue. However, the use of the third-generation lentiviral vector makes it much safer. As a result, some pre-clinical applications of the lentiviral vector have been reported to treat different diseases. 23, 24, 42 In addition, we demonstrated here a high specificity for LV-18E6-1, which kill only HeLa cells but not other cervical carcinoma cells without HPV18 E6, C33A and SiHa. We have also shown that nonspecific effects on cell growth and viability are limited with both LV-18E6-2 and LV-PLL. These data support the concept of using LV-18E6-1 as a specific anticancer treatment, although new and safer delivery systems should also be explored. The challenges now could be to develop appropriate and specific clinical delivery strategies to achieve positive treatment outcomes.
